Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Thought Leadership
Rare diseases
Pharmacists and specialty pharmacies in rare disease commercialisation
Thought Leadership
Rare diseases
Key strategies for a successful European drug launch
Thought Leadership
Rare diseases
Commercialization of rare & orphan products in Switzerland and smaller EU Markets
Thought Leadership
Rare diseases
Expand into Europe: unlocking the orphan drug market
News
Rare diseases
Rare disease day 2025
Thought Leadership
Rare diseases
Beyond compliance: unlocking the strategic potential of PASS in rare disease therapy
Events
Rare diseases
World Orphan Drug Congress USA 2025
Blogs
Rare diseases
The developing role of gene therapy in finding solutions to rare diseases
Blogs
Rare diseases
Strategic timing: When should biotech firms consider launching expanded access programs?